UA73292C2 - Method for prevention or delay of need for catheter-based revascularization in patients suffering from coronary artery disease via using statins - Google Patents

Method for prevention or delay of need for catheter-based revascularization in patients suffering from coronary artery disease via using statins Download PDF

Info

Publication number
UA73292C2
UA73292C2 UA2001042933A UA2001042933A UA73292C2 UA 73292 C2 UA73292 C2 UA 73292C2 UA 2001042933 A UA2001042933 A UA 2001042933A UA 2001042933 A UA2001042933 A UA 2001042933A UA 73292 C2 UA73292 C2 UA 73292C2
Authority
UA
Ukraine
Prior art keywords
patients
atorvastatin
study
cholesterol
group
Prior art date
Application number
UA2001042933A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22289955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA73292(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of UA73292C2 publication Critical patent/UA73292C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
UA2001042933A 1998-09-30 1999-08-07 Method for prevention or delay of need for catheter-based revascularization in patients suffering from coronary artery disease via using statins UA73292C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10245798P 1998-09-30 1998-09-30
PCT/US1999/015385 WO2000018395A1 (en) 1998-09-30 1999-07-08 Method for preventing or delaying catheter-based revascularization

Publications (1)

Publication Number Publication Date
UA73292C2 true UA73292C2 (en) 2005-07-15

Family

ID=22289955

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2001042933A UA73292C2 (en) 1998-09-30 1999-08-07 Method for prevention or delay of need for catheter-based revascularization in patients suffering from coronary artery disease via using statins

Country Status (34)

Country Link
US (1) US20080119561A1 (de)
EP (1) EP1117392B1 (de)
JP (1) JP2002525321A (de)
KR (1) KR20010079955A (de)
CN (1) CN1197565C (de)
AP (1) AP1708A (de)
AT (1) ATE260100T1 (de)
AU (1) AU768474B2 (de)
BG (1) BG105471A (de)
BR (1) BR9914098A (de)
CA (1) CA2343299C (de)
CZ (1) CZ20011035A3 (de)
DE (1) DE69915084T2 (de)
DK (1) DK1117392T3 (de)
EA (1) EA007427B1 (de)
EE (1) EE200100199A (de)
ES (1) ES2214872T3 (de)
HR (1) HRP20010236A2 (de)
HU (1) HUP0103648A3 (de)
ID (1) ID30255A (de)
IL (2) IL141953A0 (de)
IS (1) IS5889A (de)
NO (1) NO20011615L (de)
NZ (1) NZ510500A (de)
OA (1) OA11787A (de)
PL (1) PL346980A1 (de)
PT (1) PT1117392E (de)
SI (1) SI1117392T1 (de)
SK (1) SK4122001A3 (de)
TR (1) TR200100901T2 (de)
UA (1) UA73292C2 (de)
WO (1) WO2000018395A1 (de)
YU (1) YU23901A (de)
ZA (1) ZA200102230B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL353199A1 (en) 1999-08-30 2003-11-03 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
AU2001256278A1 (en) * 2000-04-18 2001-10-30 Bayer Aktiengesellschaft Use of cse inhibitors for treating heart failure
KR20030023698A (ko) * 2000-07-14 2003-03-19 워너-램버트 캄파니 카르복시알킬에테르를 사용하여 섭식 장애를 치료하는 방법
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
EP1601668B1 (de) 2003-03-07 2008-08-27 Schering Corporation Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CA2517572C (en) 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
AU1095695A (en) * 1993-11-09 1995-05-29 Brigham And Women's Hospital Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction
US5957916A (en) * 1994-05-25 1999-09-28 The Trustees Of Columbia University In The City Of New York Myocardial revascularization through the endocardial surface using a laser
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
WO1997016184A1 (en) * 1995-11-02 1997-05-09 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration
SE506272C2 (sv) * 1996-03-18 1997-11-24 Paul Edholm Förfarande och anordning för att bestämma bildläge och bildvinkel i en röntgenbild
IL117702A0 (en) * 1996-03-28 1996-07-23 Tel Aviv Medical Center Resear Drug for hyperlipoproteinemia
AU3667297A (en) * 1996-07-09 1998-02-02 Merck & Co., Inc. Therapy for combined hyperlipidemia
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
OA11787A (en) 2005-07-26
BG105471A (bg) 2001-12-31
DE69915084D1 (de) 2004-04-01
YU23901A (sh) 2003-07-07
EP1117392B1 (de) 2004-02-25
DE69915084T2 (de) 2004-07-22
NZ510500A (en) 2003-10-31
HRP20010236A2 (en) 2002-04-30
CA2343299C (en) 2008-04-01
CA2343299A1 (en) 2000-04-06
TR200100901T2 (tr) 2001-08-21
KR20010079955A (ko) 2001-08-22
CZ20011035A3 (cs) 2001-10-17
EA200100370A1 (ru) 2001-10-22
HUP0103648A2 (hu) 2003-08-28
US20080119561A1 (en) 2008-05-22
EA007427B1 (ru) 2006-10-27
HK1042436A1 (en) 2002-08-16
IL141953A0 (en) 2002-03-10
HUP0103648A3 (en) 2003-10-28
DK1117392T3 (da) 2004-06-14
EE200100199A (et) 2002-06-17
SI1117392T1 (en) 2004-06-30
NO20011615D0 (no) 2001-03-29
ATE260100T1 (de) 2004-03-15
ES2214872T3 (es) 2004-09-16
AU768474B2 (en) 2003-12-11
PL346980A1 (en) 2002-03-11
IS5889A (is) 2001-03-14
CN1197565C (zh) 2005-04-20
ID30255A (id) 2001-11-15
AU4975099A (en) 2000-04-17
NO20011615L (no) 2001-04-24
IL141953A (en) 2006-07-05
EP1117392A1 (de) 2001-07-25
ZA200102230B (en) 2002-06-18
AP1708A (en) 2007-01-10
BR9914098A (pt) 2001-07-31
SK4122001A3 (en) 2002-06-04
CN1342072A (zh) 2002-03-27
AP2001002112A0 (en) 2001-06-30
WO2000018395A1 (en) 2000-04-06
PT1117392E (pt) 2004-07-30
JP2002525321A (ja) 2002-08-13

Similar Documents

Publication Publication Date Title
US20080119561A1 (en) Methods for preventing or delaying catheter- based resvascularization
Cacciatore et al. Angina pectoris
CN101217952B (zh) 用于预防心血管事件发病的组合物
US6180660B1 (en) Cholesterol-lowering therapy
US8343947B2 (en) Therapeutic treatment
RS50485B (sr) Terapeutske kombinacije koje sadrže amplodipin i atorvastatin
ES2287009T3 (es) Sal mutua de amlodipina y atorvastatina.
JP2001514224A (ja) アムロジピンとスタチン化合物を含む併用療法
JP2024527023A (ja) Ｈｉｓ低応答者の治療
JP2002508320A (ja) スタチン−カルボキシアルキルエーテル配合物
Richartz et al. Reversibility of coronary endothelial vasomotor dysfunction in idiopathic dilated cardiomyopathy: acute effects of vitamin C
Odoemene et al. Ureterolithiasis: management in an environment with limited facilities
Kurata et al. Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia
CA2692457A1 (en) Treatment of cardiovascular disease with salicylates
Chilton et al. The expanding role of HMG-CoA reductase inhibitors (statins) in the prevention and treatment of ischemic heart disease
Hirsch et al. Intermittent claudication
RU2857461C1 (ru) Способ литокинетической терапии после дистанционной ударно-волновой литотрипсии при уролитиазе у детей
US20030191177A1 (en) Fomulation
Bоkiyev et al. THE IMPORTANCE OF SOME SYNTHETIC DRUGS AND HORSERADISH IN THE TREATMENT OF ATHEROSCLEROSIS
Andryskowski et al. Effect of calcium lactate supplementation on cholesterol concentration in patients with hyperlipidaemia and previous viral hepatitis: a preliminary report: cardiovascular topics
UA145355U (uk) Спосіб лікування болю та запалення
De Marchena et al. Angiographic demonstration of atherosclerotic stenosis, arterial spasm, and thrombus formation in an infarct‐related coronary artery
UA146735U (uk) Фармацевтичний препарат для лікування болю та запалення
WO2012116997A1 (en) TREATMENT OF ARTERIAL AGEING BY HMG CoA REDUCTASE INHIBITOR
Hagerty Comparing Two Different Statins in a Delayed Pharmacological Treatment for Ischemic Stroke